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To the Editor,
Al-Husayni and Hassoun state that “CDC recommendations for diagnosis and plan of 
treatment do not reflect latest advances in diagnostic methods and lack emphasis on 
antimicrobial stewardship and infection prevention in the healthcare setting,” argue for RT-
PCR to be the initial influenza test performed, and object to empiric antiviral treatment of 
influenza [1]. Unfortunately, they have misinterpreted CDC guidance and clarification is 
indicated.
RT-PCR is the most accurate influenza test and is recommended, especially in hospitalized 
patients with pneumonia and suspected influenza [2–4]. In ambulatory settings, RT-PCR is 
generally not available and timely results may not be available to inform clinical 
management. In some hospitals, influenza RT-PCR testing is a send-out test with results 
taking one day or longer. CDC provides guidance to clinicians and public health on the 
strengths and limitations of available influenza tests and how to properly interpret results 
[2,5]. CDC recognizes that many clinicians use rapid influenza diagnostic tests (RIDTs); 
however, CDC provides guidance recommending caution on their use, and states the 
disadvantages of RIDTs: “sub-optimal test sensitivity, false negative results are common, 
especially when influenza activity is high” [5].
CDC recommends empiric antiviral treatment with a neuraminidase inhibitor (NAI) (oral 
oseltamivir or inhaled zanamivir) as soon as possible for any outpatient in a group at higher 
risk for complications from influenza or for any hospitalized patient with suspected or 
confirmed influenza [6]. This is because (1) RIDTs lack sensitivity to detect influenza 
viruses in upper respiratory tract specimens compared to RT-PCR [7]; (2) the priority is to 
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treat those at highest risk for developing more severe disease and hospitalizations; and (3) 
observational studies of hospitalized influenza patients indicate that early initiation of 
antiviral treatment provides the greatest clinical benefit, especially for influenza 
A(H1N1)pdm09 virus infection [8–10].
The authors claim that providing antiviral treatment to patients without influenza can lead to 
“greater risk of toxicity, adverse effects and antiviral or anti-bacterial resistance,” and that 
increased use of NAI’s “increases the likelihood of antiviral resistance development” [1]. 
Whereas inappropriate antibacterial use can lead to emergence of antibiotic resistance by 
host bacteria, there is no impact of antiviral treatment upon antiviral resistance if the patient 
does not have influenza. The increase in oseltamivir resistance to seasonal influenza 
A(H1N1) viruses during 2007–2009 was linked to increased transmissibility of resistant 
strains unrelated to use of NAI’s [11]. High prevalence of oseltamivir-resistant seasonal 
H1N1 viruses was first noted in Scandinavian countries with low oseltamivir usage whereas 
low prevalence of oseltamivir resistance was observed in Japan where oseltamivir treatment 
for influenza has been widespread for many years. Sporadic cases of oseltamivir-resistant 
H1N1pdm09 virus infection have been detected, including in some nosocomial outbreaks; 
however, the prevalence of circulating oseltamivir-resistant H1N1pdm09 virus remains low 
[12].
CDC infection prevention guidance for seasonal influenza in healthcare settings emphasizes 
standard and droplet precautions and isolation or cohorting of symptomatic patients with 
suspected or laboratory-confirmed influenza [13]. Implementation of such measures should 
not be delayed while testing results are pending, and can be beneficial for preventing spread 
of other respiratory viruses that also cause influenza-like illness.
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